Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

"Köpfe" der aktuellen Meldungen:

Nina Höller

Nariae Baik-Schneditz

Bernhard Schwaberger

Lukas Peter Mileder

Niels Hammer

Gerhard Pichler

Roland Malli

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Roeseler, E; Julius, U; Heigl, F; Spitthoever, R; Heutling, D; Breitenberger, P; Leebmann, J; Lehmacher, W; Kamstrup, PR; Nordestgaard, BG; Maerz, W; Noureen, A; Schmidt, K; Kronenberg, F; Heibges, A; Klingel, R; Pro(a)LiFe-Study Group.
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Arterioscler Thromb Vasc Biol. 2016; 36(9):2019-2027 Doi: 10.1161/ATVBAHA.116.307983 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-Autor*innen der Med Uni Graz: März Winfried
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Lipoprotein(a)-hyperlipoproteinemia (Lp(a)-HLP) along with progressive cardiovascular disease has been approved as indication for regular lipoprotein apheresis (LA) in Germany since 2008. We aimed to study the long-term preventive effect of LA and to assess hypothetical clinical correlations of apolipoprotein(a) (apo(a)) by analyzing genotypes and phenotypes. This prospective observational multicenter study included 170 patients with Lp(a)-HLP and progressive cardiovascular disease (48.9 years median age at diagnosis) despite other cardiovascular risk factors, including low-density lipoprotein cholesterol had maximally been treated (mean baseline low-density lipoprotein cholesterol: measured, 2.56 mmol/L [98.9 mg/dL] and corrected, 1.72 mmol/L [66.3 mg/dL]). Patients were prospectively investigated during a 5-year period about annual incidence rates of cardiovascular events. In addition, apo(a) isoforms and polymorphisms at the apo(a) gene (LPA) were characterized. One hundred fifty-four patients (90.6%) completed 5 years of follow-up. Mean Lp(a) concentration before commencing regular LA was 108.1 mg/dL. This was reduced by a single LA treatment by 68.1% on average. Significant decline of the mean annual cardiovascular event rate was observed from 0.58±0.53 2 years before regular LA to 0.11±0.15 thereafter (P<0.0001); 95.3% of patients expressed at least 1 small apo(a) isoform. Small apo(a) isoform (35.2%) carrying phenotypes were not tagged by single-nucleotide polymorphisms rs10455872 or rs3798220. Results of 5 years of prospective follow-up confirm that LA has a lasting effect on prevention of cardiovascular events in patients with Lp(a)-HLP. Patients clinically selected by progressive cardiovascular disease were characterized by a highly frequent expression of small apo(a) isoforms. Only Lp(a) concentration seemed to comprehensively reflect Lp(a)-associated cardiovascular risk, however. © 2016 American Heart Association, Inc.
Find related publications in this database (using NLM MeSH Indexing): Aged -; Apoprotein(a) - blood; Biomarkers - blood; Blood Component Removal - adverse effects; Blood Component Removal - methods; Cardiovascular Diseases - blood; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Female -; Follow-Up Studies -; Genetic Predisposition to Disease -; Germany -; Humans -; Hyperlipoproteinemias - blood; Hyperlipoproteinemias - epidemiology; Hyperlipoproteinemias - genetics; Hyperlipoproteinemias - therapy; Incidence -; Lipoprotein(a) - blood; Lipoprotein(a) - genetics; Male -; Middle Aged -; Phenotype -; Polymorphism, Single Nucleotide -; Prospective Studies -; Risk Assessment -; Risk Factors -; Time Factors -; Treatment Outcome -
Find related publications in this database (Keywords): cardiovascular disease; coronary disease; lipoprotein(a); lipoprotein apheresis; risk factors